Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) interview with Dr. Seth Lederman, MD, CEO.


New to The Street T.V. brings back the CEO at Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP), Dr. Seth Lederman, MD. During the interview with T.V. Anchor Jane King, Dr. Lederman explains how the TNXP’s fibromyalgia drug, TNX-102 SL, could help alleviate those with Long COVID symptoms. Chronic widespread pain, non-restorative sleep, fatigue, and impaired cognition (brain fog) are symptoms found within 1/3 of those who have contracted long-covid, similar to those with fibromyalgia. The U.S. Food and Drug Administration (FDA) recently cleared TNXP for an Investigational New Drug (IND) application to support a Phase 2 clinical trial using TNX-102 SL as a potential treatment for patients with Long COVID. There is an expectation that millions inflicted with Long COVID across the U.S. and worldwide will cause a significant burden on health care systems. In the U.K., 25% apparently cannot work. Dr. Lederman talks about TNX-102 SL’s mid-Phase 3 development for managing fibromyalgia. Using a dissolvable sublingual tablet to improve sleep is not a typical sleeping pill with many side effects. A good sleep cycle is essential in helping crack the code in patients with fibromyalgia. Dr. Lederman sees an opportunity to help many with the TNX- 102 SL.

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: